Annual General Meeting of Novo Nordisk A/S (26 February 2010)
| Read the full announcement including attachments in PDF format |
Annual General Meeting on 24 March 2010
The ordinary Annual General Meeting will be held on
Wednesday 24 March 2010 at 2.00 pm (CET)
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
| Media: | Investors: |
|
|
|
| Mike Rulis | Klaus Bülow Davidsen |
| Tel: (+45) 4442 3573 | Tel: (+45) 4442 3176 |
|
|
|
|
| Kasper Roseeuw Poulsen |
|
| Tel: (+45) 4442 4471 |
|
| |
|
|
|
| In North America: | In North America: |
| Sean Clements | Hans Rommer |
| Tel: (+1) 609 514 8316 | Tel: (+1) 609 919 7937 |
Company Announcement no 11 / 2010
The notice for the Annual General Meeting and proposal for revised Incentive Guidelines are attached.
More about RSS feeds
